When patients with EGFR-mutant or ALK-translocated advanced NSCLC progress after all available targeted therapies, do you use chemotherapy or PD-1/PD-L1 inhibitor therapy as the next line?

In general I favor chemotherapy or a clinical trial for patients with sensitizing EGFR mutations after they have exhausted available EGFR TKI therapy. The EGFR mutated subgroups in both the nivolumab second line registration trials and the pembrolizumab second line registration trial trended toward ...